Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results

Autor:	Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH
Jazyk:	angličtina
Rok vydání:	2019
Předmět:	COPD tiotropium olodaterol exacerbations modeling QALYs costs Diseases of the respiratory system RC705-779
Zdroj:	International Journal of COPD, Vol Volume 14, Pp 447-456 (2019)
Druh dokumentu:	article
ISSN:	1178-2005
Popis:	Martine Hoogendoorn,1 Isaac Corro Ramos,1 Michael Baldwin,2 Laura Luciani,3 Cecile Fabron,4 Bruno Detournay,4 Maureen PMH Rutten-van Mölken1,5 1institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, the Netherlands; 2Boehringer Ingelheim GmbH, Ingelheim, Germany; 3Boehringer Ingelheim France, Paris, France; 4Cemka-Eval, Bourg-la-Reine, France; 5Erasmus School of Health Policy & Management (ESHPM), Erasmus University Rotterdam, Rotterdam, the Netherlands Purpose: Combinations of long-acting bronchodilators are recommended to reduce the rate of COPD exacerbations. Evidence from the DYNAGITO trial showed that the fixed-dose combination of tiotropium + olodaterol reduced the annual rate of total exacerbations (P
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/9a39ea2270f141fdb86043bb51418e07 Zobrazit plný text záznamu View record in DOAJ